Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer

Chad Tang, Cato Chan, Wen Jiang, James D. Murphy, Rie Von Eyben, A. Dimitrios Colevas, Harlan Pinto, Nancy Lee-Enriquez, Christina Kong, Quynh Thu Le

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). Methods. Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). Results. Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. Conclusion. This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC.

Original languageEnglish (US)
Pages (from-to)386-392
Number of pages7
JournalHead and Neck
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Platinum
Chemoradiotherapy
Combination Drug Therapy
Therapeutics
Disease-Free Survival
Cetuximab
Karnofsky Performance Status
Recurrence
Survival
Comorbidity
Drug Therapy

Keywords

  • Cetuximab
  • Chemoradiation
  • Head and neck cancer
  • Human papillomavirus
  • Platinum-based chemotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. / Tang, Chad; Chan, Cato; Jiang, Wen; Murphy, James D.; Von Eyben, Rie; Colevas, A. Dimitrios; Pinto, Harlan; Lee-Enriquez, Nancy; Kong, Christina; Le, Quynh Thu.

In: Head and Neck, Vol. 37, No. 3, 01.03.2015, p. 386-392.

Research output: Contribution to journalArticle

Tang, C, Chan, C, Jiang, W, Murphy, JD, Von Eyben, R, Colevas, AD, Pinto, H, Lee-Enriquez, N, Kong, C & Le, QT 2015, 'Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer', Head and Neck, vol. 37, no. 3, pp. 386-392. https://doi.org/10.1002/hed.23609
Tang, Chad ; Chan, Cato ; Jiang, Wen ; Murphy, James D. ; Von Eyben, Rie ; Colevas, A. Dimitrios ; Pinto, Harlan ; Lee-Enriquez, Nancy ; Kong, Christina ; Le, Quynh Thu. / Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. In: Head and Neck. 2015 ; Vol. 37, No. 3. pp. 386-392.
@article{257f36e024b54c82b72111bab34680fd,
title = "Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer",
abstract = "Background. The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). Methods. Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). Results. Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. Conclusion. This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC.",
keywords = "Cetuximab, Chemoradiation, Head and neck cancer, Human papillomavirus, Platinum-based chemotherapy",
author = "Chad Tang and Cato Chan and Wen Jiang and Murphy, {James D.} and {Von Eyben}, Rie and Colevas, {A. Dimitrios} and Harlan Pinto and Nancy Lee-Enriquez and Christina Kong and Le, {Quynh Thu}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/hed.23609",
language = "English (US)",
volume = "37",
pages = "386--392",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer

AU - Tang, Chad

AU - Chan, Cato

AU - Jiang, Wen

AU - Murphy, James D.

AU - Von Eyben, Rie

AU - Colevas, A. Dimitrios

AU - Pinto, Harlan

AU - Lee-Enriquez, Nancy

AU - Kong, Christina

AU - Le, Quynh Thu

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background. The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). Methods. Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). Results. Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. Conclusion. This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC.

AB - Background. The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). Methods. Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). Results. Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. Conclusion. This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC.

KW - Cetuximab

KW - Chemoradiation

KW - Head and neck cancer

KW - Human papillomavirus

KW - Platinum-based chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84923071369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923071369&partnerID=8YFLogxK

U2 - 10.1002/hed.23609

DO - 10.1002/hed.23609

M3 - Article

C2 - 24431011

AN - SCOPUS:84923071369

VL - 37

SP - 386

EP - 392

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 3

ER -